Year Founded
2017
Ownership
Public
Employees
~50
Therapeutic Areas
HematologyOncology
Stage
Phase 1
Modalities
Autologous cell therapyCAR T cell therapy (CAR-T)

Allife Medical Science and Technology General Information

Company is running clinical trials using CRISPR-modified cellular therapies for beta-thalassemia and cancers

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Allife Medical Science and Technology's pipeline data

Book a demo

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Allife Medical Science and Technology Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Allife Medical Science and Technology's complete valuation and funding history, request access »